(RTTNews) - Amgen (AMGN) and Kyowa Kirin Co., Ltd. announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...

For the third time, Newsweek, in collaboration with market research partner Statista, recognizes the Most Trustworthy Companies in America in 23 industries according to U.S. residents' evaluations ...

A two-member Appeals Court bench, comprising Acting President of the Court of Appeal Mohamed Lafar Tahir and Justice Sarath Dissanayake... Three newly appointed Court of Appeal Justices were formally ...

Tuesday 11th March, 2025 The JVP-led NPP government engages in smoke and mirrors with the same finesse as a professional... Saturday 8th March, 2025 What is unfolding in Sri Lanka’s law enforcement ...

Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference ...

Pre-Market: 8:33:11 a.m. EDT Loading Chart for AMGN ...

Its efficacy and safety have not been established. AGMB-129 is an oral, small molecule GI-restricted inhibitor of ALK5 (or TGF-β RI) currently in clinical development for the treatment of ...